TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22552978

Group type: EXPERIMENTAL
Intervention: Phase III COG trial for de novo acute myeloid leukemia
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: First chemotherapy course
Number of subjects: 416
Study: 20683457

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 136
Study: 18460997

Group type: EXPERIMENTAL
Intervention: Maximal strength training (half-squats, 4 sets of 4 repetitions, 3 times per week for 8 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (normal endurance training)
Number of subjects: 17
Study: 15737446

Group type: EXPERIMENTAL
Intervention: Walking with divided attention (dual-task)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Walking without divided attention (single-task)
Number of subjects: 20
Study: 14595306

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 244
Study: 10979948

Group type: EXPERIMENTAL
Intervention: Tacrolimus and methotrexate (n = 90)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cyclosporine and methotrexate (n = 90)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tacrolimus and methotrexate
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cyclosporine and methotrexate
Number of subjects: 180
Study: 8963141

Group type: EXPERIMENTAL
Intervention: Standard Octopus strategy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dynamic strategy of Weber
Number of subjects: 23
Study: 1414967

Group type: EXPERIMENTAL
Intervention: MUFAs diet
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PUFAs diet
Number of subjects: 38
Study: 3932271

Group type: EXPERIMENTAL
Intervention: L-thyroxine administration during radiation therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no L-thyroxine)
Number of subjects: 20
Study: 30660342

Group type: EXPERIMENTAL
Intervention: Intravenous NSAIDs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Trigger Point Injection (TPI)
Number of subjects: 54
Study: 28845548

Group type: EXPERIMENTAL
Intervention: Topical adhesive pads
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (untreated zone)
Number of subjects: 39
Study: 25353306

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 96
Study: 24518790

Group type: EXPERIMENTAL
Intervention: Noninvasive maximum urinary flow
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Noninvasive flow voiding time
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Detrusor pressure at maximum flow
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Hypocontractility
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Bladder contractility index
Number of subjects: 945
Study: 23508598

Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (UST)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Sham UST
Number of subjects: 455
Study: 19789442

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 366

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 366
Study: 18088346

Group type: EXPERIMENTAL
Intervention: Formal EQA scheme (patients performing tests independently at home)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supervised group (practices with supervision)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venous sample compared with patients' POC device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients' POC compared with reference POC
Number of subjects: 0
Study: 15678047

Group type: EXPERIMENTAL
Intervention: Surgical membrane (CV Seprafilm, Genzyme, Cambridge, Mass) applied in 350 patients
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Control group of 10 random reoperated patients
Number of subjects: 1024
Study: 12543738

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 57
Study: 10778966

Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) expression levels
Number of subjects: 243

Group type: COMPARATOR
Intervention: Preoperative irradiation therapy (five doses of 5 Gy each)
Number of subjects: 243
Study: 8863014

Group type: EXPERIMENTAL
Intervention: 320 ml of red wine (providing 30 g/day of alcohol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 g/day of alcohol diluted in 320 ml of clear fruit juice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 320 ml of dealcoholised red wine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Abstinence (4 weeks of complete withdrawal from any alcoholic beverage)
Number of subjects: 11
Study: 1523877

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (6.3 ng)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (12.5 ng)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (25 ng)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (6.3-25 ng)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (12.5 ng and 25 ng)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 2994989

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 24
Study: 31771407

Group type: EXPERIMENTAL
Intervention: Higher carbohydrates intake
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dietary carbohydrate in GG genotype carriers
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dietary protein in AA/AG carriers
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dietary carbohydrate in AA/AG carriers
Number of subjects: 84
Study: 28855226

Group type: EXPERIMENTAL
Intervention: Antibiotic (cephalexin if <6 months or co-trimoxazole if >6 months old) administered a day prior to VCUG and continued for 1 day post VCUG
Number of subjects: 120

Group type: COMPARATOR
Intervention: No antibiotic (control group)
Number of subjects: 120
Study: 26678954

Group type: EXPERIMENTAL
Intervention: Screening starting at age 52 with 9 screens
Number of subjects: 3488

Group type: EXPERIMENTAL
Intervention: Screening starting at age 55 with 7 screens
Number of subjects: 3488

Group type: EXPERIMENTAL
Intervention: Screening starting at age 60 with 5 screens
Number of subjects: 3488

Group type: EXPERIMENTAL
Intervention: Complete attendees (3 to 9 invitations)
Number of subjects: 3488

Group type: EXPERIMENTAL
Intervention: Age at termination of screening
Number of subjects: 3488
Study: 25268910

Group type: EXPERIMENTAL
Intervention: Cognitive behaviorally oriented interventions
Number of subjects: 84
Study: 22474933

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT adhesive
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond adhesive
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 76
Study: 20438536

Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 40
Study: 17689407

Group type: EXPERIMENTAL
Intervention: Circuit training (45 minutes, 3 times per week, for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 19080672

Group type: EXPERIMENTAL
Intervention: oral metronidazole sustained release tablet 750 mg/day for 7 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: oral metronidazole sustained release tablet 750 mg/day for 7 days and vaginal tinidazole 250 mg for 7 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: oral tinidazole 1 g/day for 3 days (2 g for the first dose)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 3 days and vaginal tinidazole 250 mg for 7 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 3 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose and vaginal tinidazole 250 mg for 7 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose
Number of subjects: 278
Study: 15003546

Group type: EXPERIMENTAL
Intervention: Lactose-based dry powder inhalers (DPIs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-lactose-based dry powder inhalers (DPIs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Metered dose inhalers (MDIs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: All inhalers tested
Number of subjects: 14
Study: 11239759

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a (IFNalpha-2a)
Number of subjects: 0
Study: 9231841

Group type: EXPERIMENTAL
Intervention: Octreotide (somatostatin analogue)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7965311

Group type: EXPERIMENTAL
Intervention: Postoperative instructions with descriptive information regarding potential sequelae and analgesic use
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic open-ended postoperative wound care instructions
Number of subjects: 40
Study: 3309236

Group type: EXPERIMENTAL
Intervention: Inhaled amikacin (100 mg twice a day) as adjunct to intravenous ceftazidime (250 mg/kg/day) and amikacin (33 mg/kg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intravenous therapy only (ceftazidime 250 mg/kg/day and amikacin 33 mg/kg/day)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both regimens (inhaled amikacin and intravenous therapy)
Number of subjects: 87
Study: 31494275

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 152

Group type: COMPARATOR
Intervention: Tonic Spinal Cord Stimulation (SCS)
Number of subjects: 152
Study: 31424158

Group type: EXPERIMENTAL
Intervention: Random Forest models for predicting viscosities of ionic liquids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOLMAP codification system
Number of subjects: 0
Study: 27296955

Group type: COMPARATOR
Intervention: Anorganic bovine bone graft (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No graft (test)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 12
Study: 25234941

Group type: EXPERIMENTAL
Intervention: Diabetic patients (liver-ROI)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (127 patients without diabetes)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus group (liver-ROI/heart-ROI ratio)
Number of subjects: 66
Study: 24944062

Group type: EXPERIMENTAL
Intervention: Stable-isotope-labeled folic acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Labeled 5‐formyltetrahydrofolic acid (5‐FormylTHF)
Number of subjects: 6
Study: 22011810

Group type: EXPERIMENTAL
Intervention: Children of postpartum depressed mothers
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Girls of postpartum depressed mothers
Number of subjects: 29

Group type: COMPARATOR
Intervention: Community sample children
Number of subjects: 29

Group type: COMPARATOR
Intervention: Girls in the community sample
Number of subjects: 29
Study: 19304918

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation using a 25-mm 15-gauge monopolar cool-tip needle electrode in temperature-controlled mode
Number of subjects: 34
Study: 17468789

Group type: EXPERIMENTAL
Intervention: ActiGait implanted drop-foot stimulator
Number of subjects: 15
Study: 16351030

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 400 mg liquid tid plus eradication treatment (500 mg clarithromycin bid and 30 mg lansoprazole bid for 10 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Eradication treatment only (500 mg clarithromycin bid and 30 mg lansoprazole bid for 10 days)
Number of subjects: 70
Study: 12140494

Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation (RSI) with Midazolam and succinylcholine before laryngoscopy, and rocuronium after tube placement confirmation.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation (RSI)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paramedic rapid sequence intubation (RSI) performed on scene
Number of subjects: 114
Study: 9800234

Group type: EXPERIMENTAL
Intervention: Nurse-conducted intervention (3 visits over 12 months)
Number of subjects: 222

Group type: COMPARATOR
Intervention: General practitioner appointment (1 visit)
Number of subjects: 222
Study: 7897108

Group type: EXPERIMENTAL
Intervention: Initial medical treatment
Number of subjects: 13412

Group type: EXPERIMENTAL
Intervention: Initial surgical treatment
Number of subjects: 13412

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 13412
Study: 2565266

Group type: EXPERIMENTAL
Intervention: Ranitidine plus bromazepam (300 mg ranitidine and 6 mg bromazepam)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ranitidine plus placebo (300 mg ranitidine and placebo)
Number of subjects: 30
Study: 1218169

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.25% bupivacaine with adrenaline
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.5% bupivacaine with adrenaline
Number of subjects: 13
Study: 30599756

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 28421246

Group type: EXPERIMENTAL
Intervention: Intravenous polyspecific immunoglobulin G (IVIG) 25 g once daily for the first 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) equal volume once daily for the first 3 days
Number of subjects: 100
Study: 26027863

Group type: EXPERIMENTAL
Intervention: BSSRO with extraction of the third molar
Number of subjects: 60

Group type: COMPARATOR
Intervention: BSSRO without extraction of the third molar
Number of subjects: 60
Study: 23777245

Group type: EXPERIMENTAL
Intervention: MobileMums program (12-week text message program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MobileMums program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal contact control group
Number of subjects: 0
Study: 22230999

Group type: EXPERIMENTAL
Intervention: R-appliance
Number of subjects: 50

Group type: COMPARATOR
Intervention: AIBP
Number of subjects: 50
Study: 19337810

Group type: EXPERIMENTAL
Intervention: Therapeutic home exercise
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intraarticular hyaluronate injection
Number of subjects: 102
Study: 16924992

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE, Kuraray)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One‐Step (ONS, BISCO Inc)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OptiBond SOLO Plus (OPS, Kerr)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (APL, 3M ESPE)
Number of subjects: 30
Study: 15117994

Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 174
Study: 11473325

Group type: EXPERIMENTAL
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic Papillary Balloon Dilation (EBD)
Number of subjects: 60
Study: 9466102

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms and epidural saline
Number of subjects: 58

Group type: COMPARATOR
Intervention: Epidural bupivacaine 20 mg and intrathecal saline
Number of subjects: 58
Study: 7948823

Group type: EXPERIMENTAL
Intervention: Serum carcinoembryonic antigen
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ascitic fluid carcinoembryonic antigen
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ascitic fluid carbohydrate antigen 19-9
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Serum-ascites albumin gradient
Number of subjects: 123
Study: 3332866

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 10
Study: 31525441

Group type: EXPERIMENTAL
Intervention: Simultaneous PDT (blue light started immediately after ALA application for 30, 45, or 60 minutes)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional PDT (blue light started 1 hour after ALA application for 1000 seconds)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both regimens (Simultaneous and Conventional PDT)
Number of subjects: 23
Study: 31125308

Group type: EXPERIMENTAL
Intervention: Tide Free and Gentle® (TFG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All Free Clear® (AFC)
Number of subjects: 0
Study: 28349381

Group type: EXPERIMENTAL
Intervention: Subdural drain
Number of subjects: 215

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 215
Study: 25785905

Group type: EXPERIMENTAL
Intervention: Autologous cell harvesting (ACH) device
Number of subjects: 10

Group type: COMPARATOR
Intervention: Meshed split-thickness skin graft (MSTSG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ACH
Number of subjects: 10

Group type: COMPARATOR
Intervention: MSTSG
Number of subjects: 10
Study: 23981403

Group type: EXPERIMENTAL
Intervention: Homeopathic complex (20% alcohol)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (unmedicated vehicle)
Number of subjects: 46
Study: 21419169

Group type: EXPERIMENTAL
Intervention: Influenza virus-like particles (VLPs) containing hemagglutinin (HA), NA, and M1 proteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NA inhibition (NAI) assay
Number of subjects: 0
Study: 19606048

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.15 mg/kg in 100 ml of isotonic saline)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline (equal volume to morphine group)
Number of subjects: 62
Study: 17062945

Group type: EXPERIMENTAL
Intervention: Group I: 1 microg/kg tramadol + 2 mg/kg propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group II: 1 mg/kg tramadol + 2 mg/kg propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group III: 50 mg flurbiprofen axetil + 2 mg/kg propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group IV: 2 mg/kg propofol
Number of subjects: 80
Study: 15298771

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus fermentum RC‐14, daily oral intake for 2 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11213852

Group type: EXPERIMENTAL
Intervention: Single dose of ketoconazole 200 mg plus placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single dose of citalopram 40 mg plus placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single dose of ketoconazole 200 mg plus single dose of citalopram 40 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9761084

Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dosage 104+/‐37 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: d,l‐sotalol (mean dosage 242+/‐109 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 70

Group type: COMPARATOR
Intervention: d,l‐sotalol
Number of subjects: 70
Study: 7920957

Group type: EXPERIMENTAL
Intervention: Head of bed elevation from 15 degrees to 60 degrees over 5.5 hours
Number of subjects: 120

Group type: COMPARATOR
Intervention: Head of bed maintained at 15 degrees or less for 5.5 hours
Number of subjects: 120
Study: 10288062

Group type: EXPERIMENTAL
Intervention: Proactive side effect management (SEM) information
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard information provided in the setting (Control)
Number of subjects: 60
Study: 31624035

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1526
Study: 27876429

Group type: EXPERIMENTAL
Intervention: Polyacrylic acid
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lubricant
Number of subjects: 52
Study: 25769357

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 14348

Group type: COMPARATOR
Intervention: Higher-dose edoxaban (60 mg)
Number of subjects: 14348

Group type: COMPARATOR
Intervention: Lower-dose edoxaban (30 mg)
Number of subjects: 14348

Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 14348
Study: 23729585

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months (first cycle)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (no CR)
Number of subjects: 251
Study: 22916516

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone as submucosal injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 40
Study: 19268383

Group type: EXPERIMENTAL
Intervention: Continual insulin injection
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Alternation of two‐month insulin injection and four‐month secretagogue treatment
Number of subjects: 536

Group type: COMPARATOR
Intervention: Continual secretagogue administration
Number of subjects: 536
Study: 16854236

Group type: EXPERIMENTAL
Intervention: Supervised treatment with artemether-lumefantrine (A/L)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Unsupervised treatment with artemether-lumefantrine (A/L)
Number of subjects: 479
Study: 15023204

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12700619

Group type: EXPERIMENTAL
Intervention: Multi‐micronutrient supplementation (3.5 g/l)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Anthelminthic treatment (albendazole 600 mg and praziquantel 40 mg/kg)
Number of subjects: 977
Study: 11000782

Group type: EXPERIMENTAL
Intervention: Method 1 PCA
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Method 2 PCA
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Method 3 PCA
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: All PCA methods
Number of subjects: 301
Study: 8842667

Group type: EXPERIMENTAL
Intervention: Continuous blockade of the lumbar plexus with bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 1468996

Group type: EXPERIMENTAL
Intervention: Integrative-learning-based (IL) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study: 6587443

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol and progesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 17 beta-estradiol alone
Number of subjects: 0